Semarion key facts
as of Oct 2026- Developer of a drug discovery and cell microcarrier platform designed to revolutionize adherent cell screening.
- Semarion is valued at approximately $39.6M as of Oct 2026 (last reported valuation).
- It has raised $7.0M; the latest was Later Stage VC ($3.8M) in Mar 2025.
- Notable investors include The FSE Group, Parkwalk Advisors, Cambridge Enterprise Ventures, Oxford Innovation Finance, Cambridge Capital Group — 10 tracked in total.
- Status: Privately Held (backing).
Semarion's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·Watch Semarion: the Monday email on marks, rounds and moves
Semarion funding rounds
No funding rounds for Semarion are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Semarion valuation
Semarion's last reported valuation was $39.6 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
Semarion investors
10 investors are on record for Semarion, including The FSE Group, Parkwalk Advisors, Cambridge Enterprise Ventures and Oxford Innovation Finance.
About Semarion
Developer of a drug discovery and cell microcarrier platform designed to revolutionize adherent cell screening. The company's platform leverages novel materials physics to provide microcarriers that function as ultra-miniaturized, magnetically steerable wells, carrying small colonies of cells to enable more powerful assay workflows and new experimental paradigms, allowing researchers to focus on advancing novel drugs for unmet medical needs.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2018
- Employees
- 10
- Website
- semarion.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.